See more : Indorama Ventures Public Company Limited (INDOY) Income Statement Analysis – Financial Results
Complete financial analysis of Forte Biosciences, Inc. (FBRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Forte Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- IFB Industries Limited (IFBIND.BO) Income Statement Analysis – Financial Results
- G-III Apparel Group, Ltd. (GIII) Income Statement Analysis – Financial Results
- BVZ Holding AG (BVZN.SW) Income Statement Analysis – Financial Results
- Agri Dynamics, Inc. (AGDY) Income Statement Analysis – Financial Results
- NexPoint Residential Trust, Inc. (NXRT) Income Statement Analysis – Financial Results
Forte Biosciences, Inc. (FBRX)
About Forte Biosciences, Inc.
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 18.04M | 41.00K | 49.00K | 51.00K |
| Cost of Revenue | 9.00K | 0.00 | 36.00K | 54.00K | 11.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -9.00K | 0.00 | -36.00K | -54.00K | -11.00K | 18.04M | 41.00K | 49.00K | 51.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 21.86M | 5.59M | 13.85M | 10.00M | 2.68M | 50.46M | 29.11M | 27.22M | 19.17M |
| General & Administrative | 10.62M | 8.30M | 7.63M | 4.22M | 1.38M | 265.68K | 8.56M | 4.52M | 3.83M |
| Selling & Marketing | -9.00K | 0.00 | 0.00 | 0.00 | 0.00 | 12.54M | -292.00K | -255.00K | -232.00K |
| SG&A | 10.62M | 8.30M | 7.63M | 4.22M | 1.38M | 12.81M | 8.27M | 4.27M | 3.60M |
| Other Expenses | -1.00 | 17.00K | -222.00K | -205.00K | -6.85K | 0.00 | 0.00 | -50.00K | 0.00 |
| Operating Expenses | 32.48M | 13.90M | 21.49M | 14.23M | 4.06M | 63.26M | 37.38M | 31.49M | 22.77M |
| Cost & Expenses | 32.49M | 13.90M | 21.49M | 14.23M | 4.06M | 63.89M | 37.67M | 31.74M | 23.01M |
| Interest Income | 1.12M | 0.00 | 0.00 | 0.00 | 0.00 | 595.00K | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 173.38K | 1.93M | -1.84M | -102.00K | |
| Depreciation & Amortization | 9.00K | 36.00K | 36.00K | 54.00K | 11.00K | 625.00K | 292.00K | 255.00K | 232.00K |
| EBITDA | -32.48M | -13.90M | -21.45M | -46.43M | -4.05M | -43.69M | -36.71M | -31.17M | -22.49M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -250.77% | -91,065.85% | -64,155.10% | -44,552.94% |
| Operating Income | -32.49M | -13.90M | -21.49M | 17.83M | -4.06M | -45.85M | -37.63M | -31.69M | -22.95M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -254.23% | -91,778.05% | -64,675.51% | -45,007.84% |
| Total Other Income/Expenses | 1.01M | 17.00K | -222.00K | -205.00K | -5.00K | -1.40M | -1.30M | -1.79M | -102.00K |
| Income Before Tax | -31.48M | -13.88M | -21.71M | -46.49M | -4.07M | -47.26M | -38.93M | -33.48M | -23.06M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -262.01% | -94,948.78% | -68,322.45% | -45,207.84% |
| Income Tax Expense | 0.00 | -17.00K | -200.56K | 32.06M | -2.52K | 1.70M | -2.60M | -3.67M | -204.00K |
| Net Income | -31.48M | -13.86M | -21.71M | -78.54M | -4.07M | -48.96M | -38.93M | -33.48M | -23.06M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -271.43% | -94,948.78% | -68,322.45% | -45,207.84% |
| EPS | -24.92 | -19.96 | -38.85 | -157.93 | -48.25 | -915.18 | -997.50 | -634.80 | -474.15 |
| EPS Diluted | -24.92 | -19.96 | -38.85 | -157.93 | -48.25 | -915.18 | -997.50 | -634.80 | -474.15 |
| Weighted Avg Shares Out | 1.26M | 695.34K | 558.71K | 294.36K | 84.33K | 53.49K | 38.95K | 52.74K | 48.63K |
| Weighted Avg Shares Out (Dil) | 1.26M | 695.34K | 558.71K | 294.36K | 84.33K | 53.49K | 38.95K | 52.74K | 48.63K |
Forte Biosciences, Inc. to Present at the Chardan Annual Microbiome Medicines Summit on March 8th
TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, announced today that Paul Wagner, Ph.D., CEO of Forte Biosciences will be presenting at the Chardan Annual Microbiome Medicines Summit on March 8th, 2021. Webcast Information Forte management...
Forte Biosciences, Inc. to Present at the Cowen Annual Health Care Conference on March 1st
TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, announced today announced that Paul Wagner, Ph.D., CEO of Forte Biosciences will be presenting at the Cowen Annual Health Care Conference on March 1, 2021. Webcast Information Forte...
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte’s...
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte's...
Forte Biosciences: FB-401 Potentially Best-In-Class In Atopic Dermatitis
FB-401 is a unique approach to atopic dermatitis containing three strains of bacteria that have shown the ability to induce tissue repair and reduce inflammation. FB-401 may present efficacy and safety advantages over commercial and clinical stage treatments.
Forte Biosciences, Inc. to Present at the Evercore ISI 3rd Annual HealthCONx Conference on December 3rd
TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, announced today announced that Paul Wagner, Ph.D., CEO of Forte Biosciences will be presenting at the Evercore ISI Annual HealthCONx Conference on December 3, 2020. Webcast Information Forte...
Forte Biosciences, Inc. Reports Inducement Grants Under NASDAQ Listing Rules
TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of...
Forte Biosciences, Inc. to Present at the Stifel 2020 Virtual Healthcare Conference on November 18th
TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, announced today announced that Paul Wagner, Ph.D., CEO of Forte Biosciences will be presenting at the Stifel 2020 Virtual Healthcare Conference. Webcast Information Forte management will host a...
Forte Biosciences, Inc. Announces Third Quarter 2020 Results and Provides General Business Update
TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced third quarter 2020 financial results and provided a general business update. “This was an eventful quarter for Forte with significant progress in advancing FB-401 for the...
Forte Biosciences, Inc. Announces Third Quarter 2020 Results and Provides General Business Update
TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced third quarter 2020 financial results and provided a general business update. “This was an eventful quarter for Forte with significant progress in advancing FB-401 for the...
Source: https://incomestatements.info
Category: Stock Reports